Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00866515




Registration number
NCT00866515
Ethics application status
Date submitted
22/01/2009
Date registered
20/03/2009
Date last updated
18/07/2017

Titles & IDs
Public title
Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole
Scientific title
A Double-blind, Placebo-controlled, Randomised, 2-way Crossover Drug Interaction Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects Following Co-administration of GW642444M With Ketoconazole
Secondary ID [1] 0 0
112205
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Disease, Chronic Obstructive 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ketoconazole + GW642444M
Treatment: Drugs - Placebo + GW642444M

Experimental: Active - Ketoconazole 400mg OD days 1-6

Placebo Comparator: Placebo - Placebo OD for 1 to 6 days


Treatment: Drugs: Ketoconazole + GW642444M
Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5

Treatment: Drugs: Placebo + GW642444M
Placebo to match D1-6 + GW642444M 25ug single dose on D5
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Supine heart rate and blood potassium levels
Timepoint [1] 0 0
Day 5
Secondary outcome [1] 0 0
Plasma GW642444M concentrations
Timepoint [1] 0 0
Day 5
Secondary outcome [2] 0 0
Reported Adverse Events
Timepoint [2] 0 0
treatment periods

Eligibility
Key inclusion criteria
- Healthy as determined by a responsible and experienced physician, based on a medical
evaluation including medical history, physical examination, laboratory tests and
cardiac monitoring. A subject with a clinical abnormality or laboratory parameters
outside the reference range for the population being studied may be included at the
discretion of the Investigator only if the finding is unlikely to introduce additional
risk factors and will not interfere with the study procedures.

- AST, ALT, alkaline phosphatase and bilirubin = 1.5xULN (isolated bilirubin >1.5xULN is
acceptable if bilirubin is fractionated and direct bilirubin <35%).

- Male or female between 18 and 65 years of age inclusive, at the time of signing the
informed consent.

- A female subject is eligible to participate if she is of:

- Non-childbearing potential defined as pre-menopausal females with a documented tubal
ligation, hysterectomy or bilateral oophorectomy; or postmenopausal defined as 12
months of spontaneous amenorrhea [in questionable cases a blood sample with
simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml
(<140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose
menopausal status is in doubt will be required to use one of the contraception methods
in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they
must discontinue HRT to allow confirmation of post-menopausal status prior to study
enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation
of therapy and the blood draw; this interval depends on the type and dosage of HRT.
Following confirmation of their post-menopausal status, they can resume use of HRT
during the study without use of a contraceptive method.

- Child-bearing potential and agrees to use one of the contraception methods listed in
Section 8.1 for an appropriate period of time (as determined by the product label or
investigator) prior to the start of dosing to sufficiently minimize the risk of
pregnancy at that point. Female subjects must agree to use contraception until after
the final follow-up visit has been completed.

- Body weight = 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive).

- Demonstrated ability to use the inhaler device in a satisfactory and repeatable manner

- Subjects who are current non-smokers, who have not used any inhaled tobacco products
(snuff is permitted) in the 12 month period preceding the screening visit and who have
a pack history of = 10 pack years.

- No significant abnormality on 12-lead ECG at screening, including the following
requirements:

- Ventricular rate = 40 beats per minute

- PR interval = 120 and = 210 msec

- Q waves < 30 msec (up to 50 msec permitted in lead III only)

- QRS interval to be = 60 msec and = 120 msec

- QTc interval must be < 450 msec (QTcB or QTcF; machine or manual reading) based on an
average from three ECGs obtained over a brief recording period

- FEV1 = 80% predicted and a FEV1 / FVC ratio = 0.7 at screening

- Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- As a result of medical interview, physical examination or screening investigations,
the principle investigator or delegate physician deems the subject unsuitable for the
study.

- Systolic blood pressure which is outside the range 90 to 140 mmHg, diastolic blood
pressure outside the range 50 to 90 mmHg or heart rate outside the range 40 to 90 bpm.

- The subject has been treated for or diagnosed with depression within six months of
screening or has a history of significant psychiatric illness.

- The subject has any history of breathing problems in adult life (i.e. history of
asthmatic symptomatology).

- A clinically significant abnormality on standard pulmonary function testing, or any
other finding that would prevent satisfactory administration of the inhaled study
medication.

- Any contraindication to the administration of ketoconazole, as described in the
current [NIZORAL Product Information, Janssen-Cilag Pty Limited, 2008].

- History of sensitivity to any of the study medications, or components thereof
(including milk protein) or a history of drug or other allergy that, in the opinion of
the investigator or GSK Medical Monitor, contraindicates their participation.

- Currently taking regular (or a course of) medication whether prescribed or not, with
the exception of those permitted medications listed in Section 8.1 and Section 9.1.

- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
dose of study medication, unless in the opinion of the Investigator and GSK Medical
Monitor the medication will not interfere with the study procedures or compromise
subject safety.

- History of regular alcohol consumption within 6 months of the study defined as:

- An average weekly intake of >21 units for males or >14 units for females. One unit is
equivalent to 8 g of alcohol: a half-pint (~250 mL) of beer, 1 glass (100 mL) of wine
or 1 measure (30 mL) of spirits.

- The subject has participated in a clinical trial and has received a drug or a new
chemical entity within 30 days or 5 half-lives, or twice the duration of the
biological effect of any drug (whichever is longer) prior to the first dose of current
study medication.

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.

- The subject has donated a unit of blood within the previous 16 weeks or intends to
donate within 16 weeks after completing the study.

- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
result within 3 months of screening.

- The subject has tested positive for HIV antibodies.

- The subject has a positive pre-study urine drug screen/ alcohol breath test. A minimum
list of drugs that will be screened for include Amphetamines, Barbiturates, Cocaine,
Opiates, Cannabinoids and Benzodiazepines.

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.

- Unwillingness or inability to follow the procedures outlined in the protocol.

- Subjects who have a screening haemoglobin value < 110 mg/L.

- Pregnant (as determined by positive (serum or urine) hCG test at screening or prior to
dosing) or lactating females.

- Subject is mentally or legally incapacitated.

- CO breath monitoring indicative of smoking or history or regular use of tobacco- or
nicotine-containing products within 6 months prior to screening.

- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or
pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior
to the first dose of study medication.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/12/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/03/2009
Sample size
Target
Accrual to date
Final
20
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
GSK Investigational Site - Randwick
Recruitment postcode(s) [1] 0 0
2031 - Randwick

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This will be a single-centre, randomised, double blind, placebo controlled, two-way crossover
study in healthy male and female subjects. There will be two treatment periods each
consisting of 7 days. During each treatment period subjects will receive single doses of
ketoconazole or placebo on the morning of days 1-6 with a single dose of GW642444M on the
morning of Day 5.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00866515
Trial related presentations / publications
Kempsford R, Allen A, Bal J, Rubin D, Tombs L. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2013 Jun;75(6):1478-87. doi: 10.1111/bcp.12019.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00866515